Zobrazeno 1 - 10
of 345
pro vyhledávání: '"Susana Banerjee"'
Autor:
Jarushka Naidoo, Maria L Ascierto, Matthew D Hellmann, Ding Wang, Susana Banerjee, Mayukh Das, Panagiotis Kourtesis, Jennifer R Diamond, Teresa Alonso-Gordoa, Sandip P Patel, Nathan E Standifer, Doug C Palmer, Lin-Yang Cheng, Benedito A Carneiro
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background The combination of monalizumab (anti-NKG2A/CD94) and durvalumab (anti-programmed death ligand-1) may promote antitumor immunity by targeting innate and adaptive immunity. This phase 1/2 study of monalizumab and durvalumab evaluated safety,
Externí odkaz:
https://doaj.org/article/53d0d5cbaca340b3995a64a938291778
Autor:
Ana Oaknin, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo Gancedo, Peter C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Susana Banerjee, Jesus García‐Donas, Elizabeth M. Swisher, Terri Cameron, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 7162-7173 (2021)
Abstract Background The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum‐based chemotherapy and baseline disease. Methods Patients were randomized 2:1 to rec
Externí odkaz:
https://doaj.org/article/2cbcf9c399a94021b6832bbcf96e807d
Autor:
Ana Oaknin, Maria-Pilar Barretina-Ginesta, Victor Moreno, Thierry André, Ruth Plummer, Florence Joly, Rowan Miller, Joanna Pikiel, Susana Banerjee, Jose Manuel Trigo Perez, Bhavana Pothuri, Andrea Jewell, Anna Tinker, Dominique Berton, Susan Ellard, Jennifer Veneris, Tao Duan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d39ea0b42267479e959567a5b2a0f1fd
Autor:
Saira Khalique, Stephen J Pettitt, Ger Kelly, Nina Tunariu, Rachael Natrajan, Susana Banerjee, Christopher J Lord
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 6, Iss 1, Pp 3-11 (2020)
Abstract Development of resistance to platinum and poly(ADP‐ribose) polymerase inhibitors via secondary BRCA gene mutations that restore functional homologous recombination has been observed in a number of cancer types. Here we report a case of som
Externí odkaz:
https://doaj.org/article/e8f9e42757ad4610a7b154b67b6a4093
Autor:
Sidra Nawaz, Nicholas A. Trahearn, Andreas Heindl, Susana Banerjee, Carlo C. Maley, Andrea Sottoriva, Yinyin Yuan
Publikováno v:
EBioMedicine, Vol 48, Iss , Pp 224-235 (2019)
Background: Despite treatment advances, there remains a significant risk of recurrence in ovarian cancer, at which stage it is usually incurable. Consequently, there is a clear need for improved patient stratification. However, at present clinical pr
Externí odkaz:
https://doaj.org/article/704d0afd473e4cad85d11af14f6cf40b
Autor:
Andreas Heindl, Adnan Mujahid Khan, Daniel Nava Rodrigues, Katherine Eason, Anguraj Sadanandam, Cecilia Orbegoso, Marco Punta, Andrea Sottoriva, Stefano Lise, Susana Banerjee, Yinyin Yuan
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Cancer cells can actively engage in overcoming microenvironmental constraints such as tissue stiffness through adapting their shapes; however it is unclear how microenvironmental cells shape cancer nuclear morphology in human tumors in situ. Here the
Externí odkaz:
https://doaj.org/article/80aafabf129a42f2a86063973bcb2266
Autor:
Susana Banerjee, Holly Tovey, Rebecca Bowen, Elizabeth Folkerd, Lucy Kilburn, Jennifer McLachlan, Marcia Hall, Nina Tunariu, Ayoma Attygalle, Joao Paulo Da Silveira Nogueira Lima, Sophie Perry, Peter Chatfield, Margaret Hills, Stan Kaye, Gert Attard, Mitch Dowsett, Judith M. Bliss
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits
Externí odkaz:
https://doaj.org/article/573e022757c443b698c2911c247d9712
Autor:
Philipp Harter, Ana Oaknin, Isabelle Ray-Coquard, Domenica Lorusso, Kathleen N Moore, Antonio Gonzalez-Martin, Susana Banerjee
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines Agency and Food and Drug Admin
Externí odkaz:
https://doaj.org/article/244e856198f544068a835c710b8f23b9
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
Externí odkaz:
https://doaj.org/article/90052ef9d0e4444fa96da39829f90bc8
Autor:
Emma Lidington, Anne-Sophie Darlington, Amy Din, Susannah Stanway, Susana Banerjee, Zoltan Szucs, Michael Gonzalez, Anand Sharma, Bhawna Sirohi, Winette T. A. van der Graaf, Olga Husson
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 19, p 4449 (2021)
Few studies describe supportive care needs among young adults (YAs) with cancer ages 25 to 39 using validated questionnaires. Previous findings identified the need for psychological and information support and suggest that gender, age, psychological
Externí odkaz:
https://doaj.org/article/21f4c47bee5646ef99d7fb7f1e733013